EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

4. What is the difference between 503A and 503B GLP-1 compounding for clinics?

Dose Diligence research deskSection 01 · Page 4 of 34Last updated 17 Nov 2026

503A generally centres on identified patients and prescriptions; 503B is an outsourcing-facility pathway that can accommodate non-patient-specific supply when its conditions are met. Neither designation independently makes a particular GLP-1 preparation eligible. (fda.gov)

IssueSection 503ASection 503B
Typical operatorLicensed pharmacist in a qualifying pharmacy or licensed physicianRegistered outsourcing facility
Patient-specific prescriptionGenerally required, with limited anticipatory compounding provisionsNot necessarily required
Manufacturing frameworkQualifying drugs receive specified exemptions, including from CGMPCGMP obligations remain
Copying restrictionsRestrictions on regularly or inordinately compounding essentially copiesSeparate restrictions on essentially copies of approved drugs
Bulk ingredientsMust satisfy 503A ingredient conditionsMust satisfy separate 503B bulk-substance conditions

These distinctions come from FDA’s statutory comparison and outsourcing-facility materials. (fda.gov)

Buyer action: identify the actual producing facility and pathway for each preparation. A corporate group with both pharmacy and outsourcing operations should not be evaluated as one undifferentiated supplier.

Explore the table row by row

A working view of the research

Typical operator

Section 503A
Licensed pharmacist in a qualifying pharmacy or licensed physician
Section 503B
Registered outsourcing facility

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
Section sources →